Provided by Tiger Fintech (Singapore) Pte. Ltd.

Arcutis Biotherapeutics Inc.

15.24
+0.59004.03%
Post-market: 15.300.0600+0.39%19:58 EDT
Volume:1.57M
Turnover:23.80M
Market Cap:1.81B
PE:-13.16
High:15.58
Open:14.75
Low:14.74
Close:14.65
Loading ...

Arcutis Biotherapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
26 Feb

Stock Track | Arcutis Biotherapeutics (ARQT) Soars 8.36% After Hours on Robust Q4 Earnings Beat and ZORYVE Sales Growth

Stock Track
·
26 Feb

Arcutis Biotherapeutics Q4 2024 GAAP EPS $(0.09) Beats $(0.24) Estimate, Sales $71.400M Beat $60.160M Estimate

Benzinga
·
26 Feb

Arcutis Biotherapeutics Q4 Operating Income USD -7.632 Million VS. Ibes Estimate USD -26.6 Million

THOMSON REUTERS
·
26 Feb

Arcutis Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

GlobeNewswire
·
26 Feb

Arcutis Biotherapeutics announces publication of data from INTEGUMENT-PED trial

TIPRANKS
·
24 Feb

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
21 Feb

Wall Street Analysts Think Arcutis Biotherapeutics (ARQT) Could Surge 51.64%: Read This Before Placing a Bet

Zacks
·
17 Feb

Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO) and Arcutis Biotherapeutics (ARQT)

TIPRANKS
·
17 Feb

Ultragenyx (RARE) Reports Q4 Loss, Tops Revenue Estimates

Zacks
·
14 Feb

Arcutis Biotherapeutics (ARQT) Surges 15.9%: Is This an Indication of Further Gains?

Zacks
·
13 Feb

Arcutis Biotherapeutics rumor highlighted in Betaville alert

TIPRANKS
·
13 Feb

Here's Why Arcutis Biotherapeutics (ARQT) Could be Great Choice for a Bottom Fisher

Zacks
·
11 Feb

Arcutis Soared In 2024, Blazing Trails In Dermatology. Why Its CEO Eyes Bigger Gains.

Blockhead
·
06 Feb

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
06 Feb

Recent 4.4% pullback isn't enough to hurt long-term Arcutis Biotherapeutics (NASDAQ:ARQT) shareholders, they're still up 118% over 1 year

Simply Wall St.
·
01 Feb

Are Medical Stocks Lagging Addus HomeCare (ADUS) This Year?

Zacks
·
28 Jan

Arcutis Biotherapeutics Receives Buy Rating Amid Strong Prescription Growth in Zoryve Franchise

TIPRANKS
·
27 Jan

Strong Prescription Growth for Arcutis Biotherapeutics’ Zoryve Franchise Supports Buy Rating

TIPRANKS
·
20 Jan

Arcutis Biotherapeutics price target raised to $20 from $18 at Needham

TIPRANKS
·
13 Jan